BLEX 404 + pemetrexed + cisplatin

BLEX 404 + pemetrexed + cisplatin is an investigational combination regimen consisting of three agents: - **BLEX 404** is an oral liquid formulation derived from Maitake mushroom, standardized for β-glucan polysaccharides with a unique molecular structure (1,6 main chain with 1,3 branches and vice versa). These β-glucans have immunomodulatory properties, notably enhancing macrophage, T cell, and natural killer cell activity, as well as increasing granulocyte colony-stimulating factor (G-CSF) production and overall hematopoiesis. The antitumor effects are mediated via immune system activation, suggesting BLEX 404’s role as an immunotherapeutic agent[1][3][9]. - **Pemetrexed** is a small molecule antimetabolite (folate analogue metabolic inhibitor) that disrupts folate-dependent metabolic processes essential for cell replication, inhibiting thymidylate synthase and other folate-dependent enzymes, thereby blocking DNA synthesis and inhibiting proliferation of rapidly dividing cells, including cancer cells[2][4][6][8]. - **Cisplatin** is a platinum-based chemotherapy that forms DNA crosslinks, leading to apoptosis through inhibition of DNA synthesis and function[2][4][6][8]. The combination is being evaluated for safety, optimal dosing, and preliminary efficacy in advanced, nonsquamous non-small cell lung cancer (NSCLC) and other oncology settings[1][3][9].